Renexxion

Renexxion is committed to gaining approval for naronapride and becoming a leading gastrointestinal biopharmaceutical company, providing benefits to patients in need. Naronapride is an orally administered gastroprokinetic agent in the late stage of development, phase 3 ready, belonging to the class of 5-HT4 agonists, which has demonstrated efficacy across a range of these conditions.